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Abstract—DNA microarray-based gene expression
profiles have been established for a variety of
adult cancers. This paper addresses application of
an artificial neural network (ANN) with leave-one-
out testsing and 8-fold cross-validation for analyz-
ing DNA microarray data to identify genes predic-
tive of recurrence after prostatectomy. Among 725
genes screened for ANN input, a 16-gene model re-
sulted in 99-100% diagnostic sensitivity and speci-
ficity: DGCR5, FLJ10618, RIS1, PRO1855, ABCB9,
AK057203, GOLGA5, HARS, AK024152, HEP27,
PPIA, SNRPF, SULT1A3, SECTM1, EIF4EBP1, and
S71435. Genes identified with ANN that are prognostic
of prostate cancer recurrence may be either causal for
prostate cancer or secondary to the disease. Neverthe-
less, the genes identified may be confirmed in the future
to be markers of early detection and/or therapy.
I. Introduction
Prostate cancer is the 2nd leading cause of cancer mor-
tality among US males[1]. For locally confined cancer, cu-
rative treatment includes radical prostatectomy [2,3] and
radiotherapy[4-7]. Following prostatectomy, it is expected
that serum levels of prostate specific antigen (PSA) remain
fixed below a level of 0.2 ng/ml. However, approximately
15-35% of patients experience PSA (biochemical) recur-
rence defined as two or more successive follow-up values
of PSA>0.2 ng/ml more than 30 days post-surgery [8-11].
Early biochemical recurrence occurring before 1 year post-
surgery is strongly associated with metastatic disease in
approximately 75% of male patients[12]. However, clin-
ical and pathological factors are imperfect predictors of
biochemical recurrence. Thus, it is of interest to augment
clinical information with prognostic information derived
from molecular markers of aggressive disease.
Research for identifying biomarkers as a supplement
to clinical information for prostate cancer has increased
tremendously over the last decade. With regard to gene
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expression studies on recurrence, Lapointe et al identified
a set of 23 genes whose expression levels were either
positively or negatively associated with early recurrence
in a set of 7 prostate cancers with early recurrence and
22 non-recurrent tumors[13]. Singh et al [14] studied gene
expression of 12,600 genes in 21 prostate cancers (8 recur-
rent, 13 non-recurrent), and defined a set of 5 genes whose
expression levels resulted in 90% accuracy of class predic-
tion. Glinsky et al [15] performed additional xenograft-
based analyses on the same data set and derived three
five-gene models resulting in 95% classification accuracy.
Lastly, Yu and colleagues [16] looked at a 70-gene leave-
one-out classification model for 29 aggressive tumors and
37 non-aggressive tumors and obtained 86% classification
accuracy.
There is growing interest in the application of ANNs
in microarray analysis[17-21]. The majority of these pa-
pers conclude unique and superior classification results
obtained with ANNs when compared with other classifiers.
In this report, we applied an artificial neural network
(ANN) to identify microarray-based genes with the great-
est class-specific sensitivity for predicting PSA recurrence
of prostate cancer. Two-color oligonucleotide microarrays
were employed for generating patient gene expression
profiles. The set of genes identified may ultimately be
used to provide additional prognostic information in men
with prostate cancer that will be useful for evaluation of
prognosis and treatment planning.
II. Methods
A. Microarray Samples and Gene Ranking
We used a total of 32 arrays for prostate cancer cases un-
dergoing radical prostatectomy. RNA was extracted from
the peripheral zone in tissue with greater than 70% tumor
pathology. Two-color 21k gene oligonucleotide arrays were
hybridized and scanned for 15 cases which experienced
post-surgical PSA recurrence <1 year (“poor outcome”)
and 17 cases which remained recurrent-free more than
5 y (“good outcome”) post-surgery. From 21,329 genes,
we identified 5,757 which had at least 95% informative
spots (G and R signal-to-noise ratio>2) within each class.
The non-parametric Mann-Whitney U test, which approx-
imates the Gini diversity index [23], of the ChipST2C
program (http://www.chipst2c.org) was used to identify
725 genes with significant rank differences (P <0.01) in
2expression between poor and good outcome. Gene ranking
resulted in a 32 × 725(A × G) E matrix of standardized
expression, where A(a = 1, 2, . . . , 32) is the number of
samples and G(g = 1, 2, . . . , 725) is the number of genes.
B. Dimensional Reduction
Dimensional reduction using k-means cluster
analysis and principal component analysis (PCA)
was performed with the ANNChip computer program
(http://www.chipst2c.org). The objective for running
k-means and PCA was to reduce the number of input
nodes to be clamped to the ANN during training. In
addition, individual gene expression values were mapped
back to the k-means centers and PC scores by use of
k-means scores and PC score coefficients. During k-means
clustering in ANNChip, the optimum number of k clusters
occurs when the ratio of the smallest between-cluster
distance to total mean-square error (grand total of error
between each gene and its mean vector) is the greatest.
K-means cluster analysis resulted in a 32 × 27(A × K)
M matrix of cluster centers, where A(a = 1, 2, . . . , 32)
is the number of samples and K(k = 1, 2, . . . , 27) is the
number of centers. Figure 1 shows a countour plot of the
M matrix of 27 centers for the 32 arrays.
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Fig. 1. M matrix of k-means centers for k = 27 clusters extracted
from the expression values of 725 genes on 32 arrays.
Because the ANN is trained on samples with 27 input
values representing the k=27 clusters, the gene expression
profiles over 32 arrays needed to be mapped to the aver-
age expression within the 27 clusters by using “k-means
scores.”
The k-means score which maps gene g to center k is
determined as
zgk =
‖xg −mk‖ − µk
σk
k = 1, 2, . . . ,K, (1)
where xg is the standardized expression vector for gene
g, mk is the mean vector for center k, ‖xg − mk‖ is
the Euclidean distance between expression for gene g and
center k, and µk and σk are the average and standard
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Fig. 2. F matrix of principal component scores for 10 PCs extracted
from the expression values of 725 genes on 32 arrays. Total variance
explained is 73.4%.
A B
Fig. 3. (A) Z matrix of k-means scores and (B) W matrix of PC
score coefficients for 725 genes, which map expression back to the
k-means centers and PC scores.
deviation of distances ‖xg − mk‖ between all genes and
center k. This was repeated for each cluster center to yield
a 725× 27(G×K) Z matrix of k-means scores.
During PCA dimensional reduction, the top 10 eigen-
values explaining 73.4% of total variation were extracted
from the 725 × 725(G × G) correlation matrix R. PCA
resulted in a 32×10(A×P ) F matrix of PC scores, where
A(a = 1, 2, . . . , 32) is the number of samples and P (p =
1, 2, . . . , 10) is the number of PCs. Figure 2 illustrates a
countour plot of the F matrix of 10 PCs for the 32 arrays.
Figure 3 shows the 725× 27(G×K) Z matrix of k-means
scores and the 725 × 10(G × P ) W matrix of PC score
coefficients, which map expression back to the k-means
centers and PC scores, respectively.
C. ANN Architecture
A multilayer perceptron with back-propagation learning
was employed as the ANN (Figure 4). When ANN training
3TABLE I
Data used in ANN training, recursive feature elimination
(RFE), and clamping criteria.
Reduction method
Data ANN usage K-means PCA
Matrices Traina M
A×K
F
A×P
RFEb Z
G×K
W
G×P
Predictionc E
A×G
E
A×G
ANN clamping
vectors
Train xa = ma xa = fa
RFE xg = zg xg = wg
Prediction xa = ea xa = ea
a Matrices M and F used for training ANN.
b Applied weights after last training epoch
against matrices Z and W looping over
all genes once to determine Egc and S
g
c .
c Class membership was predicted after retraining
ANN with standardized expression matrix E
for genes identified during RFE.
M is the matrix of k-means centers.
F is the matrix of PC scores.
Z is the matrix of k-means scores.
W is the matrix of PC score score coefficients.
E is the matrix of standardized expression.
A is the number of arrays, ( a = 1 , 2 , . . . , A) .
K is the number of k-means cluster centers, ( k = 1 , 2 , . . . , K) .
P is the number of PCs, ( p = 1 , 2 , . . . , P ) .
G is the number of genes, ( g = 1 , 2 , . . . , G) .
During RFE, G = 725 , whereas during prediction
G = 2 , 4 , 8 , 16 , 32 , 64 .
was based on k-means centers, we clamped rows of the
A × K M matrix of cluster centers to the input nodes
(i.e., xa = ma, a = 1, 2, . . . , 32). Whereas when ANN
training was based on PCA, we clamped rows of the A×P
F matrix of PC scores to the input nodes (i.e., xa = fa,
a = 1, 2, . . . , 32). The number of hidden nodes was equal
to 40% of the number of input nodes. Connection weights
wihij between the input and hidden layer and w
ho
jc between
hidden and output layers were initialized with random
uniform variates in the range [-0.5,0.5]. Node output vj at
the hidden layer were based on the logistic activation func-
tion 1/(1 + exp(−uj)), where uj =
∑
xiw
ih
ij , while node
outputs tˆc at the output layer were based on the softmax
function exp(yc)/
∑
exp(yl), where yc =
∑
vjw
ho
jc . Mean
square error (MSE) for each sample was determined as
0.5
∑
c(tˆc−tc)
2, where tˆc is the predicted target probability
of each sample being in class c and tc is the true class
probability of each sample, set to zero or unity. After
each sample was transmitted through the ANN, back-
propagation learning was performed sequentially updating
weights one sample at a time. A total of 25 epochs was per-
formed for each model, with 32 cycles (samples) per epoch.
(Models using 5000 epochs were evaluated and neither
increased overtraining or diversion of the gradient descent
toward local maxima were observed). The ANN model
fitting approach combined leave-one-out testing with 8-
cross-validation. Arrays in the validation group were not
used for training and only for prediction of class outcome,
while the remaining samples were used for training the
ANN. Last, we used a learning rate of  = 0.5, a steadily
decreasing weight decay γ, and momentum of α = 0.5.
Fig. 4. Schematic of the artificial neural network (ANN) used.
D. ANN Recursive Feature Elimination
In order to gauge the influence of each gene on the clas-
sification, target outputs tˆgc for each gene were calculated
during the last sweep of every model using the last known
weights and setting the input nodes xi equal to either the
1 × K row vector of k-means scores zg for each gene or
the 1× P row vector wg of PC score coefficients for each
gene. It warrants noting that the ANN was not retrained
here, but rather gene-specific values of tˆgc were determined
by applying the last known weights to gene-specific row
vectors of Z or W, which map the genes back to the
original M and F matrices used for training.
a) Gene Selection with Maximum Sensitivity: The
average gene-class-specific sensitivity [24] of each gene was
determined as
Sgc =
1
n
n∑
i=1
∂tˆgc
∂xi
(2)
where g is the gene, c is the class, n is the number of input
nodes based on n = K and xg = zg if the ANN was trained
with k-means centers based on M, or n = P and xg = wg
if the ANN was trained with PC scores based on F (Table
I). Class-specific sensitivities for each gene were summed
over all 256 models and then sorted in descending order.
b) Gene Selection with Minimum Error: In addition
to RFE based on sensitivity, we also calculated the gene-
class-specific mean square error during the last sweep,
using the recomputed values of tˆgc described above. Anal-
ogously, we derived lists of genes for which each class was
represented equally by genes having the lowest gene-class-
specific MSE. Recall that the predicted class target tˆgc for
each gene is class specific; however, genes do not have a
true class membership, i.e., tgc , so we calculated error as
Egc =
∑C
j 0.5(tˆ
g
c − I(j)
2, where I(j) is one if j = c and
zero if j = c.
4E. Generating Lists of Selected Genes
A modular approach was employed for generating the
list of genes identified during RFE. Lists were divided
uniformly into genes that best discriminated each outcome
class, depending on whether the selection criterion was
minimum gene-class-specific MSE or maximum gene-class-
specific sensitivity. The total number of genes in a list was
based on powers of 2 multiplied by the number of classes,
such that the list was uniformly loaded with genes that
best discriminated each class. As an example, in this two
class study, gene selection lists contained a total of 2, 4, 8,
16, 32, or 64 genes with half of the genes having the total
maximum sensitivity (or least error) for the poor outcome
and half having the maximum sensitivity (or least error)
for the good outcome class.
F. ANN Training with Selected Gene Expression Profiles
After recursive feature identification, we trained the
ANN models with the actual standardized values of ex-
pression for each list of 2, 4, 8, 16, 32, or 64 genes iden-
tified. Expression for each gene was standardized over the
arrays (using array-specific mean and s.d.) ANN clamping
involved use of the rows of the standardized expression
matrix E such that xa = ea (Table I). The number of
hidden nodes was equal to 40% of the number of input
nodes. For example, for 64 genes (features) and 2 outcome
classes a 64-26-2 network was employed. During runs with
actual gene expression profiles, we assessed accuracy and,
the proportion of between-gene correlation coefficients
that were significant (p ≤ 0.01).
G. ANN Pseudocode
The following provides the ANN algorithm used:
1) for leaveout← 1 to #Arrays
2) Randomly assign each array into O equal partitions
(o = 1, 2, ..., O)
3) for o← 1 to O
4) Initialize {wihij } and {w
ho
jc } in the range [-0.5,0.5].
5) ∆wihij ← 0, ∀i, j, ∆w
ho
jc ← 0, ∀j, c.
6) for sweep← 1 to #Epochs
7) t← 0
8) for array ← 1 to #Arrays
• uj =
∑I
i=1 xiw
ih
ij ,∀j.
• vj = 1/(1 + e
−uj ),∀j.
• yc =
∑H
j=1 vjw
ho
jc , ∀c
• tˆc = exp(yc)/{
∑
l=1 exp(yl)}, ∀c
• E = 12
∑C
c=1(tˆc − tc)
2
• Ec =
1
2
(tˆc − tc)
2
• if array /∈ o then ’training array
t = t+ 1 ’increment cycle
∆whojc (t) = −εγ(∂E/∂w
ho
jc )+α∆w
ho
jc (t−1), ∀j, c.
whojc (t) = w
ho
jc (t− 1) + ∆w
ho
jc (t),∀j, c.
∆wihij (t) = −εγ(∂E/∂w
ih
ij ) +α∆w
ih
ij (t− 1), ∀i, j.
wihij (t) = w
ih
ij (t− 1) + ∆w
ih
ij (t), ∀i, j.
• endif
• if sweep = #Epochs then ’last sweep
if array ∈ o then ’validation array
pdf(c(array))diagnosis = Ec(array)
endif
if array = leaveout then ’left out array
pdf(array)prediction = Ec(array)
endif
• endif
9) Next array
10) Next sweep
11) Call geneidentification(Sgc ).
12) Next o
13) Next leaveout
III. Results
Figures 5 and 6 show the MSE for ANN training based
on standardized expression profiles for the top 4 genes and
16 genes, respectively, identified after k-means dimensional
reduction and maximum sensitivity used as a criterion for
RFE. In Figures 5 and 6, red denotes training MSE while
blue denotes validation MSE. In Figure 5, one can notice
the overtraining that occurred as a result of ANN training
with expression profiles for only 4 genes. When the ANN
was trained with expression profiles of the top 16 genes
(Figure 6), however, there was no apparent overtraining
for the 25 epochs used.
Tables II and III list diagnostic sensitivity and speci-
ficity results of ANN modeling for the poor and good out-
come class predictions, respectively. Recall that sensitivity
is defined as the probability of correctly predicting that
an array is in class A given that the array is truly from
diagnostic class A. Specificity is defined as the probability
of correctly assigning an array to a class other than A
given that the array is truly not in class A. For the
calibration run using the k-means centers and PC scores
from all 725 probes, sensitivity and specificity ranged
from 90-100% for both outcome groups. For runs using
standardized expression for the top genes identified, at 2
genes and more, sensitivity and specificity steadily ramped
up from 70-80% for 2 genes to the greatest values in the
90% range for 64 genes. Interestingly, for k-means cluster
analysis dimensional reduction, the maximum sensitivity
and specificity for both outcomes was observed for 16-
gene models. However, for PCA dimensional reduction, the
greatest values of sensitivity and specificity were observed
among 64-gene models. These results show that, for the
training data considered, use of k-means cluster analysis
for data pre-processing, followed by cross-validation and
leave-one-out testing can provide remarkably high screen-
ing diagnostics exceeding 95%. The 16 genes identified
after k-means dimensional reduction and maximum sensi-
tivity for RFE that resulted in a sensitivity of 1.0 (in Table
II) were DGCR5, FLJ10618, RIS1, PRO1855, ABCB9,
AK057203, GOLGA5, HARS, AK024152, HEP27, PPIA,
SNRPF, SULT1A3, SECTM1, EIF4EBP1, and S71435.
These are also highlighted in bold in Table IV in the 64-
gene model.
5Fig. 5. MSE for 256 ANN models as a function of training epoch for a
4-gene model based on k-means dimensional reduction and maximum
sensitivity for RFE. Red denotes training MSE while blue denotes
validation MSE.
Fig. 6. MSE for 256 ANN models as a function of training epoch
for a 16-gene model based on k-means dimensional reduction and
maximum sensitivity for RFE. Red denotes training MSE while blue
denotes validation MSE.
Tables IV and V list the top 64 genes selected by RFE
for the 64-gene models for dimensional reduction with
k-means cluster analysis and PCA, respectively. It was
interesting to learn that the 64 genes listed were not always
the most significant genes based on the Mann-Whitney
U test used for the gene ranking. Although not shown,
the majority of the genes identified were among the least
significant (rank >300). This reflects the generalizability
of ANN models for which there is a preference to select
not the most significant genes, but rather those which
simultaneously maximize the screening diagnostics (sen-
sitivity and specificity). The genes listed in Tables IV and
V became available at the time of writing, so they are
now being mined for their roles in cancer (i.e., prostate),
GO groups, PFAM familes, secretion signals, transcription
factor binding sites in promoters, and protein interactions,
TABLE II
Diagnostic sensitivity of class prediction based on ANN
training with standardized expression for selected genes.
k-means
max{Sgc } min{E
g
c }
#Genes Poor Good Poor Good
725a 1.000 0.985 1.000 0.985
2 0.671 0.786 0.852 0.869
4 0.860 0.833 0.908 0.879
8 0.961 0.877 0.903 0.886
16c 1.000 0.991 0.959 0.884
32 0.985 0.985 0.959 0.898
64 0.961 0.960 0.991 0.924
PCA
max{Sgc } min{E
g
c }
#Genes Poor Good Poor Good
725b 0.940 0.867 0.940 0.867
2 0.708 0.816 0.746 0.687
4 0.837 0.787 0.826 0.786
8 0.774 0.770 0.768 0.763
16 0.843 0.825 0.768 0.782
32 0.869 0.882 0.869 0.863
64 0.914 0.903 0.899 0.888
a ANN trained with M matrix of k-means centers.
b ANN trained with F matrix of PC scores.
c 16 genes are listed in Table IV.
etc.
Figure 7 illustrates the significant positive and negative
between-gene correlation of expression for the 64-gene
models. Red represents significant (p < 0.01) positive
correlation coefficients, while blue denotes significant (p <
0.01) negative correlation coefficients. Panel 4A for k-
means dimensional reduction and min{Egc } shows that
0.444 of the correlation coefficients were significantly pos-
itive, panel 4B for k-means and max{Sgc } shows that only
0.185 of the correlation coefficients were significantly pos-
itive, panel 4C for PCA and min{Egc } reflects that 0.295
of the correlation coefficients were significantly positive,
and panel 4D for PCA and max{Sgc } illustrates that 0.287
of the coefficients were significantly positive. Overall, one
can note the reduced significant positive correlation for
RFE with maximum sensitivity (panels 4B and 4D), which
is accentuated for k-means dimensional reduction (panel
4B). This is in good agreement with results obtained in our
previous work using simulated and empirical expression
data from the public domain [24].
IV. Discussion and Conclusion
The purpose of this study was to compare diagnos-
tic screening results (sensitivity and specificity) and be-
tweengene correlation across dimensional reduction and
RFE methods used. The ANN analysis results obtained
demonstrate that diagnostic sensitivity and specificity in
the range 99-100% was obtained when using k-means di-
mensional reduction and maximum sensitivity for RFE for
a 16-gene model. On the other hand, for PCA dimensional
reduction, diagnostic screening results were in the 70-80%
6TABLE III
Diagnostic specificity of class prediction based on ANN
training with standardized expression for selected genes.
k-means
max{Sgc } min{E
g
c }
#Genes Poor Good Poor Good
725a 0.985 1.000 0.985 1.000
2 0.786 0.671 0.869 0.852
4 0.833 0.860 0.879 0.908
8 0.877 0.961 0.886 0.903
16 0.991 1.000 0.884 0.959
32 0.985 0.985 0.898 0.959
64 0.960 0.961 0.924 0.991
PCA
max{Sgc } min{E
g
c }
#Genes Poor Good Poor Good
725b 0.867 0.940 0.867 0.940
2 0.816 0.708 0.687 0.746
4 0.787 0.837 0.786 0.826
8 0.770 0.774 0.763 0.768
16 0.825 0.843 0.782 0.768
32 0.882 0.869 0.863 0.869
64 0.903 0.914 0.888 0.899
a ANN trained with M matrix of k-means centers.
b ANN trained with F matrix of PC scores.
range for 16 genes. In addition, dimensional reduction with
k-means cluster analysis and RFE with maximum sensi-
tivity resulted in the least amount of significant positive
between-gene correlation.
We are currently trying to understand the biological
relevance of the 64 genes identified with the various
methods. The majority of this effort involves GO mining
and development of transcription factor networks and
review by biologists to determine any differences in the
computational results. We will eventually compare results
with support vector machines, and soft computing meth-
ods, which provide alternative approaches for optimizing
decision boundaries between classes.
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